Arthroplasty is a healthcare priority and represents
high volume,
high cost surgery. Periprosthetic joint infection (PJI) results in
significant mortality, thus it is vital that the risk for PJI is minimized.
Vancomycin is recommended for surgical prophylaxis in total joint
arthroplasty (TJA) by current clinical practice guidelines endorsed
by the Infectious Diseases Society of America. This study aimed to
develop a new assay to determine vancomycin concentrations in serum
and bone, and a minimal physiologically based population PK (mPBPK)
model to evaluate vancomycin bone penetration in noninfected patients.
Eleven patients undergoing TJA received 0.5–2.0 g intravenous
vancomycin over 12–150 min before surgery. Excised bone specimens
and four blood samples were collected per patient. Bone samples were
pulverized under liquid nitrogen using a cryogenic mill. Vancomycin
concentrations in serum and bone were analyzed by liquid chromatography-tandem
mass spectrometry and subjected to mPBPK modeling. Vancomycin serum
and bone concentrations ranged from 9.30 to 86.6 mg/L, and 1.94–37.0
mg/L, respectively. Average bone to serum concentration ratio was
0.41 (0.16–1.0) based on the collected samples. The population
mean total body clearance was 2.12L/h/kg0.75. Inclusion
of total body weight as a covariate substantially decreased interindividual
variability in clearance. The bone/blood partition coefficient (K
pbone) was estimated at 0.635, reflecting the
average bone/blood concentration ratio at steady-state. The model
predicted median ratio of vancomycin area under the curve (AUC) for
bone/AUC for serum was 44%. Observed vancomycin concentrations in
bone were overall consistent with perfusion-limited distribution from
blood to bone. An mPBPK model overall well described vancomycin concentrations
in serum and bone.